Drug Profile

Nimodipine oral solution - Arbor Pharmaceuticals

Alternative Names: AR 02; Nymalize

Latest Information Update: 12 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arbor Pharmaceuticals
Class Antihaemorrhagics; Antihypertensives; Dihydropyridines; Esters; Small molecules
Mechanism of Action Calcium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Subarachnoid haemorrhage
New Molecular Entity No

Highest Development Phases

Marketed Subarachnoid haemorrhage

Most Recent Events

03 Sep 2024 Registered for Subarachnoid haemorrhage in USA (PO)
03 Sep 2024 Azurity Pharmaceuticals plans to launch nymalize prefilled ENFit syringe in the coming weeks
16 Dec 2013 Launched for Subarachnoid haemorrhage in USA (PO) before 16 December 2013 - First global launch

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com